Fludrocortisone ( DrugBank: Fludrocortisone )

3 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2
17	Multiple system atrophy	1
81	Congenital adrenal hyperplasia	2

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01993680 (ClinicalTrials.gov)	June 2012	27/4/2012	Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment	A Monocentric Randomized, Controlled, Double Blind, Crossover Phase II Trial to Show Non-inferiority of the Effect of Pyridostigmine Bromide vs. Fludrocortisone on Symptoms of Autonomic Dysregulation in Parkinson's Disease	Autonomic Disturbances in Parkinson's Disease	Drug: Pyridostigmine bromide;Drug: fludrocortisone	Christian Baumann	NULL	Completed	50 Years	80 Years	All	18	Phase 2	Switzerland
2	NCT00103597 (ClinicalTrials.gov)	January 2005	11/2/2005	Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy	Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy	Parkinson's Disease;Multiple System Atrophy;Orthostatic Hypotension	Drug: Fludrocortisone;Drug: Domperidone;Behavioral: Conservative Measures for Orthostatic Hypotension	Royal Brisbane and Women's Hospital	NULL	Completed	40 Years	95 Years	Both	50	Phase 1	Australia

Clinical trials : 119 / Drugs : 138 - (DrugBank : 44) / Drug target genes : 59 - Drug target pathways : 111

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00103597 (ClinicalTrials.gov)	January 2005	11/2/2005	Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy	Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy	Parkinson's Disease;Multiple System Atrophy;Orthostatic Hypotension	Drug: Fludrocortisone;Drug: Domperidone;Behavioral: Conservative Measures for Orthostatic Hypotension	Royal Brisbane and Women's Hospital	NULL	Completed	40 Years	95 Years	Both	50	Phase 1	Australia

Clinical trials : 87 / Drugs : 87 - (DrugBank : 23) / Drug target genes : 12 - Drug target pathways : 68

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03548246 (ClinicalTrials.gov)	January 2023	24/4/2015	Androgen Reduction in Congenital Adrenal Hyperplasia	A Phase 1-2 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase Deficiency	Congenital Adrenal Hyperplasia	Drug: Abiraterone acetate;Drug: Placebo;Drug: Hydrocortisone;Drug: Fludrocortisone	University of Texas Southwestern Medical Center	National Institutes of Health Clinical Center (CC);University of Michigan;Children's Hospital Los Angeles;Feinstein Institute for Medical Research	Withdrawn	2 Years	9 Years	All	0	Phase 2	United States
2	NCT00001521 (ClinicalTrials.gov)	June 8, 1995	3/11/1999	Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia	An Open, Randomized, Long-Term Clinical Trial of Flutamide, Testolactone, and Reduced Hydrocortisone Dose vs. Conventional Treatment of Children With Congenital Adrenal Hyperplasia	Congenital Adrenal Hyperplasia (CAH)	Drug: Flutamide;Drug: Letrozole;Drug: Hydrocortisone;Drug: Fludrocortisone	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	NULL	Active, not recruiting	2 Years	18 Years	All	62	Phase 2	United States